CTI BioPharma (CTIC) Reports Q3 Loss of $0.28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CTIC Hot Sheet
Join SI Premium – FREE
CTI BioPharma (NASDAQ: CTIC) reported Q3 EPS of ($0.28), versus ($1.04) reported last year.
For earnings history and earnings-related data on CTI BioPharma (CTIC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LTC Properties (LTC) Tops Q3 EPS by 22c
- Bristow Group (VTOL) Misses Q2 EPS by 24c ; Offers Guidance
- LATAM Airlines (LTM) Misses Q3 EPS by 135c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
